Skip to main content

Table 5 Association of ERCC2 and MTHFR haplotypes with clinical characteristics of breast cancer patients

From: Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study

Haplotype
(n = 302)
Age (years) OR (95% CI)a p b
> 40 ≤40
rs1801133-rs1801131
 C-A 49.8% c 49.4% 1
 T-A 23.9% 26.5% 1.08 (0.61–1.93) 0.78
 C-C 21.2% 8.7% 0.44 (0.16–1.16) 0.1
 T-C 5.1% 15.4% 3.52 (1.23–10.06) 0.02
rs1799793-rs13181
 G-A 51.3% 48.1% 1
 A-A 18.7% 20.7% 1.23 (0.65–2.35) 0.53
 G-C 15.5% 18.9% 1.33 (0.68–2.61) 0.41
 A-C 14.5% 12.3% 0.91 (0.47–1.76) 0.79
Haplotype Family history of breast cancer   
(n = 302) Sporadic Familial   
rs1801133-rs1801131
 C-A 53.5% 46.6% 1
 T-A 17.9% 31.1% 1.76 (0.97–3.18) 0.063
 C-C 24.5% 7.4% 0.36 (0.14–0.95) 0.042
 T-C 4.1% 14.9% 4.96 (1.50–16.42) 0.0097
rs1799793-rs13181
 G-A 51.1% 48.7% 1
 A-A 19.1% 20.2% 1.05 (0.56–1.98) 0.88
 G-C 18.4% 15.5% 0.87 (0.44–1.68) 0.67
 A-C 11.4% 15.6% 1.32 (0.70–2.47) 0.39
Haplotype ER and PR status   
(n = 286) ER positive ER negative   
rs1799793-rs13181
 G-A 46.7% 57.6% 1
 A-A 19.6% 17.4% 0.83 (0.38–1.81) 0.65
 G-C 15.9% 20.2% 1.11 (0.54–2.30) 0.78
 A-C 17.8% 4.8% 0.28 (0.09–0.88) 0.03
rs1799793-rs13181 PR positive PR negative   
 G-A 48.7% 48.3% 1
 A-A 19.3% 20.5% 1.41 (0.67–2.98) 0.36
 G-C 13.1% 25.7% 2.34 (1.1–4.96) 0.02
 A-C 18.9% 5.6% 0.33 (0.12–0.92) 0.03
Haplotype Tumor size   
(n = 72) T1 T4   
rs1799793-rs13181
 G-A 55.5% 41.7% 1
 A-A 17.4% 29.2% 2.10 (0.59–7.46) 0.26
 G-C 11.2% 29.1% 23.30 (2.03–267.69) 0.017
 A-C 15.9% 0% NA 1
  1. aOR (Odds ratio) and 95% CI (confidence interval)
  2. bbold values are statistically significant (p < 0.05), n number of halotypes
  3. c% of haplotypes, ER: estrogen receptor, PR progesterone receptor, NA not applicable
\